1,475,121 Shares in Xilio Therapeutics, Inc. (NASDAQ:XLO) Bought by Takeda Pharmaceutical Co. Ltd.

Takeda Pharmaceutical Co. Ltd. acquired a new stake in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) in the 4th quarter, Holdings Channel reports. The firm acquired 1,475,121 shares of the company’s stock, valued at approximately $1,416,000. Xilio Therapeutics accounts for about 5.3% of Takeda Pharmaceutical Co. Ltd.’s holdings, making the stock its 3rd biggest position.

Separately, Geode Capital Management LLC increased its position in shares of Xilio Therapeutics by 85.0% during the 3rd quarter. Geode Capital Management LLC now owns 338,192 shares of the company’s stock valued at $266,000 after purchasing an additional 155,337 shares during the last quarter. 54.29% of the stock is currently owned by institutional investors.

Xilio Therapeutics Stock Performance

NASDAQ:XLO opened at $0.73 on Thursday. The firm has a market capitalization of $37.95 million, a PE ratio of -0.43 and a beta of -0.38. The stock’s fifty day moving average is $0.89 and its 200 day moving average is $0.93. Xilio Therapeutics, Inc. has a fifty-two week low of $0.58 and a fifty-two week high of $1.93.

Xilio Therapeutics (NASDAQ:XLO) last released its earnings results on Tuesday, March 11th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.02. The firm had revenue of $1.72 million during the quarter, compared to the consensus estimate of $2.26 million. Equities analysts forecast that Xilio Therapeutics, Inc. will post -1.14 EPS for the current year.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.